doi:10.1007/s40268-022-00394-3
External resources STEP 1 Trial: Semaglutide in Adults with Overweight or Obesity (NEJM) SURMOUNT-1 Trial: Tirzepatide for Treatment of Obesity (NEJM) NIH BMI Calculator (National Heart, Lung, and Blood Institute) For researchers serious about navigating GLP-1 eligibility and optimizing their treatment protocols, SeekPeptides offers the most comprehensive resource available
Other articles assessed as well as studies in which their findings indicated no statistically significant increase in risk was shown have stated that there does seem to be an observed increase in aspiration events and may be a result from the observed delayed gastric emptying, which may also be attributed to the mongoose phenomenon in effect (Avraham et al
Substack Series 2 of 6, GLP-1 Receptor Agonists: Mechanisms and Clinical Applications Can another diabetes medicine be used for longevity and addiction
10.1007/s004210050579 117 Pinedo-VillanuevaR.WestburyL
Los autores de un metaanlisis de 2013 combinaron los resultados de este estudio con los de 12 estudios ms pequeos [49]
